149 related articles for article (PubMed ID: 29289982)
1. Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
Zhao H; Zhao Y; Zhang Y; Hou J; Yang H; Cao F; Yang Y; Hou W; Sun J; Jin B; Fu J; Li H; Wang P; Ge F; Zhou J
Ann Hematol; 2018 Mar; 97(3):409-416. PubMed ID: 29289982
[TBL] [Abstract][Full Text] [Related]
2. Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
Hou J; Wang S; Zhang Y; Fan D; Li H; Yang Y; Ge F; Hou W; Fu J; Wang P; Zhao H; Sun J; Yang K; Zhou J; Li X
Ann Hematol; 2017 Dec; 96(12):2005-2013. PubMed ID: 28940056
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide.
Jin B; Zhang Y; Hou W; Cao F; Lu M; Yang H; Tian X; Wang Y; Hou J; Fu J; Li H; Zhou J
J Cancer Res Clin Oncol; 2020 Feb; 146(2):485-492. PubMed ID: 31686248
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone.
Hou W; Zhang Y; Jin B; Cao W; Lu M; Yan L; Yang H; Tian X; Hou J; Fu J; Zhao H; Li H; Zhou J
Blood Cells Mol Dis; 2019 Nov; 79():102351. PubMed ID: 31400712
[TBL] [Abstract][Full Text] [Related]
5. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.
Chen X; Fan S; Zhao Y; Zhou J
Clin Transl Oncol; 2021 Oct; 23(10):2171-2180. PubMed ID: 33942222
[TBL] [Abstract][Full Text] [Related]
6. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.
Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Möllgård L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennström L; Höglund M; Juliusson G
Leukemia; 2011 Jul; 25(7):1128-34. PubMed ID: 21502956
[TBL] [Abstract][Full Text] [Related]
7. Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia.
Wen J; Xu F; Zhou Q; Shi L; Liu Y; Yue J; Zhang Y; Liang X
BMC Cancer; 2023 Jan; 23(1):27. PubMed ID: 36611025
[TBL] [Abstract][Full Text] [Related]
8. Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE).
Hassan IB; Zaabi MRA; Alam A; Hashim MJ; Tallman MS; Kristensen J
Int J Hematol; 2017 Jul; 106(1):90-98. PubMed ID: 28293819
[TBL] [Abstract][Full Text] [Related]
9. Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
Abla O; Ribeiro RC; Testi AM; Montesinos P; Creutzig U; Sung L; Di Giuseppe G; Stephens D; Feusner JH; Powell BL; Hasle H; Kaspers GJL; Dalla-Pozza L; Lassaletta A; Tallman MS; Locatelli F; Reinhardt D; Lo-Coco F; Hitzler J; Sanz MA
Ann Hematol; 2017 Sep; 96(9):1449-1456. PubMed ID: 28597167
[TBL] [Abstract][Full Text] [Related]
10. Analysis of risk factors for early death in patients with acute promyelocytic leukaemia treated with arsenic trioxide.
Wang Y; Hou W; Li H; Tian X; Li J; Hu T; Shi D; Zhang Y
Ann Hematol; 2022 May; 101(5):1039-1047. PubMed ID: 35174404
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
Labrador J; Luño E; Vellenga E; Brunet S; González-Campos J; Chillón MC; Holowiecka A; Esteve J; Bergua J; González-Sanmiguel JD; Gil C; Tormo M; Salamero O; Manso F; Fernández I; de laSerna J; Moreno MJ; Pérez-Encinas M; Krsnik I; Ribera JM; Cervera J; Calasanz MJ; Boluda B; Sobas M; Lowenberg B; Sanz MA; Montesinos P
Leuk Lymphoma; 2019 May; 60(5):1146-1155. PubMed ID: 30526152
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
[TBL] [Abstract][Full Text] [Related]
15. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
Kelaidi C; Chevret S; De Botton S; Raffoux E; Guerci A; Thomas X; Pigneux A; Lamy T; Rigal-Huguet F; Meyer-Monard S; Chevallier P; Maloisel F; Deconinck E; Ferrant A; Fegueux N; Ifrah N; Sanz M; Dombret H; Fenaux P; Adès L
J Clin Oncol; 2009 Jun; 27(16):2668-76. PubMed ID: 19414681
[TBL] [Abstract][Full Text] [Related]
16. Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.
Sobas M; Czyż A; Montesinos P; Armatys A; Helbig G; Hołowiecka A; Pluta A; Zarzycka E; Piątkowska-Jakubas B; Majcherek M; Lewandowski K; Gołos A; Paluszewska M; Podhorecka M; Oleksiuk J; Skręt A; Hawrylecka D; Guzicka-Kazimierczak RE; Wątek M; Gromek T; Charliński G; Grosicki S; Holojda J; Miśkiewicz W; Martinez-Cuadrón D; Sanz MA; Wróbel T; Wierzbowska A; Giebel S
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):105-113. PubMed ID: 31874794
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
[TBL] [Abstract][Full Text] [Related]
18. Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early death.
Zhang Y; Hou W; Wang P; Hou J; HuiyuanYang ; Zhao H; Jin B; Sun J; Cao F; Zhao Y; Li H; Ge F; Fu J; Zhou J
Cancer Manag Res; 2018; 10():3619-3627. PubMed ID: 30271210
[TBL] [Abstract][Full Text] [Related]
19. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.
Bally C; Fadlallah J; Leverger G; Bertrand Y; Robert A; Baruchel A; Guerci A; Recher C; Raffoux E; Thomas X; Leblanc T; Idres N; Cassinat B; Vey N; Chomienne C; Dombret H; Sanz M; Fenaux P; Adès L
J Clin Oncol; 2012 May; 30(14):1641-6. PubMed ID: 22473162
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
